Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

Annals of Oncology

Volumn 19, Issue 6, 2008, Pages 1141-1145

  Pfeiffer, Per ^a   Nielsen, D ^c   Bjerregaard, J ^a   Qvortrup, C ^a,b   Yilmaz, M ^d   Jensen, B ^c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Advanced colorectal cancer; Biweekly; Cetuximab; Irinotecan; Third line therapy

Indexed keywords

CAPECITABINE; CETUXIMAB; DIPHENHYDRAMINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; IRINOTECAN; OXALIPLATIN; PREDNISOLONE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANAPHYLAXIS; ARTICLE; CANCER MORTALITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 44849083804     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn020     Document Type: Article

References (16)

1. Ragnhammar P, Hafström L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282-308.
2. Meyerhardt JA, Mayer RJ. Therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487.
3. Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patents with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
4. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
5. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse. Sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
6. Kemeny N, Garay CA, Gurtler J et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patents with advanced colorectal cancer. J Clin Oncol 2004; 22: 4701-4709.
7. Pfeiffer P, Nielsen D, Yilmaz M et al. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007; 46: 697-701.
8. Nygren P, Sørbye H, Österlund P, Pfeiffer P. Targeted drugs in metastatic colorectai cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 2005; 44: 203-217.
9. Saltz LB, Meropol NJ, Loehrer PJ et al. Phase II trial of cetuximab in patents with refractory oolorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
10. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Mad 2004; 351: 337-345.
11. Pfeiffer P, Qvortrup C, Eriksen JG. The current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007; 26: 3661-3678.
12. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
13. Nielsen DL, Pfeiffer P, Jensen BV. Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports. Acta Oncol 2006; 45: 1137-1138.
14. Tabernero J, Cervantes A, Martinelli E et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol ASCO Annual meeting Proceedings Part I 2006; 24: (Abstr 3085).
15. Sørbye H, Glimelius B, Berglund Å et al. Multicentre phase II study of oxaliplatin combined with Nordic 5-fluorouracil/leucovorin bolus schedule (FLOX) as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31-38.
16. Jatoi A, Rowland K, Sloan JA et al. Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB). J Clin Oncol ASCO Annual meeting Proceedings Part I 2007; 25: (Abstr LBA9006).